A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms
Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Tiziano Barbui(University of Bergamo), Maria Luisa Ferrari(University of Bergamo), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Giovanni Barosi(Policlinico San Matteo Fondazione), Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Silvia Salmoiraghi(Ospedale Papa Giovanni XXIII), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Elisabetta Gattoni(Policlinico San Matteo Fondazione), Orietta Spinelli(Ospedale Papa Giovanni XXIII)
Cited by 32
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k